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obacteriaceae isolates, particularly Klebsiella pneumoniae
carbapenemase (KPC)-producing K. pneumoniae and New
Delhi metallo-b-lactamase-1 (NDM-1)-producing Enter-
obacteriaceae, have emerged in health care settings of
many countries.1,2 Apart from NDM, which is endemic in
the Indian subcontinent, KPC was first reported among
K. pneumoniae in the United States in 20013 and has also
been proven to possess great potential for intra- and
interhospital dissemination worldwide. The first clinical
KPC-producing K. pneumoniae isolate in Taiwan was ob-
tained in 2010 from a patient with bacteremia who had just
returned from Zhejiang Province, the epicenter of the
KPC-2 endemic in China.4 For most clinical laboratories,
however, it is difficult to judge the existence of carbape-
nemases in Enterobacteriaceae through minimum inhibitory
concentration (MIC) levels against carbapenem agents
alone.
In 2009, by means of the modified Hodge test, no
ertapenem-nonsusceptible (NS; MIC > 0.25 mg/mL) Enter-
obacteriaceae isolates of class A carbapenemase production* Corresponding author. Number 7, Chung-Shan South Road,
Taipei 100, Taiwan, ROC.
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using the MIC breakpoints recommended by the Clinical and
Laboratory Standards Institute (CLSI) in 2011, we found
alarmingly high rates of nonsusceptibility of Enterobacter
cloacae and K. pneumoniae to ertapenem (40.5% and 24.5%,
respectively).5 Subsequently, using the polymerase chain
reaction method and electrophoresis analysis, two nation-
wide surveys in Taiwan investigated the 2011 prevalence
rates of Enterobacteriaceae carriers of carbapenemases
(class A, class B)6 and elucidated the main resistance
mechanisms of carbapenem-NS Enterobacteriaceae isolates
collected in 2010 and 2012,7 respectively. The first survey,
undertaken by Lee et al,6 revealed that 5.2% (16 isolates) of
ertapenem-NS (MIC > 0.5 mg/mL, by CLSI 2012 standards)
Enterobacteriaceae isolates (all were K. pneumoniae) in
2011 harbored genes encoding KPC-2 carbapenemase.
Additionally, a similar pulsotype and the same sequence
type (ST) 11 (n Z 16) were found among all KPC-2-
producing K. pneumoniae isolates in hospitals located in
northern Taiwan. The second survey, conducted by Chiu
et al,7 revealed that the prevalence rate of resistant iso-
lates (imipenem or meropenem MIC >1.0 mg/mL, by CLSI
2012 standards) harboring various carbapenemase genes
(primarily blaKPC-2) was significantly higher in 2012 than in
2010 [22.3% (55 isolates) vs. 6.0% (6 isolates) for overallished by Elsevier Taiwan LLC. All rights reserved.
318 S.-S. Jean et al.carbapenemases, pZ 0.0003; 16.6% (41 isolates) vs. 0% for
prevalence of KPC-2 carrier among K. pneumoniae,
p < 0.0001; both were analyzed with the Chi-square test].
Apart from carbapenemases, other factors governing
resistance comprised deficiency of outer membrane protein
(Omp, especially OmpK35) and production of AmpC enzyme
(mostly DHA-1 subtype) as well as extended-spectrum b-
lactamase (ESBL, primarily blaCTX-M, followed by blaSHV).
The combination of these factors likely conferred medium-
to-high resistance to carbapenem agents (especially to
ertapenem, imipenem). Thus, in Taiwan, factors other than
carbapenemases still account for the major in vitro resis-
tance mechanisms responsible for carbapenem non-
susceptibility. In addition, typing analysis of the multilocus
sequence type revealed that the ST 11 K. pneumoniae
strain was the predominant KPC clone throughout Taiwan in
2012. These facts strongly suggest that occult interhospital
spread of KPC-K. pneumoniae in Taiwan probably emerged
in 2011.
Data on ertapenem-NS (MIC > 0.5 mg/mL) Enter-
obacteriaceae in Taiwan differ markedly from the data
obtained from the countries in the Asia Pacific region
(2008e2009)8 targeting at intra-abdominal Enter-
obacteriaceae isolates. In that large-scale survey,8 11.0% (77
isolates) of resistant isolates had genes encoding carbape-
nemases (primarily blaNDM-1, followed by blaIMP and blaOXA)
and had different AmpC enzymes (dominated by blaCMY-2).
The percentages of KPC-2 (class A) and class B b-lactamases
among all carbapenem-NS Enterobacteriaceae isolates
collected from 2010 through 20126,7 in Taiwan are illustrated
in Fig. 1.
Two surveys5,9 focusing on ertapenem-NS (MIC > 0.25 mg/
mL) Enterobacteriaceae isolates without KPC production in
Taiwan provided important in vitro susceptibility informa-
tion on b-lactam agents. Cheng et al9 found that regardless
of ESBL production, a significant portion of ertapenem-NS
isolates (45.8% of Escherichia coli, 53% of K. pneumoniae,
and 86.1% of Enterobacter cloacae isolates) was in vitro
susceptible to cefepime according to CLSI 2011 standards
(i.e., MIC level 8 mg/mL). However, the production ofFigure 1. Percentages ofAmbler classA (allwereblaKPC-2) and
class B b-lactamases (including blaIMP-8, blaNDM-1, and blaVIM-1)
among carbapenem-nonsusceptible Enterobacteriaceae iso-
lates collected from hospitals throughout Taiwan, during the
period 2010e2012.ESBL enzyme lowered the susceptibility rates to cefepime
to a large extent.9 In addition, with respect to the
ertapenem-NS Enterobacteriaceae isolates (consisting of
E. coli, K. pneumoniae, and E. cloacae) without class A
carbapenemase, Jean et al5 noted that carbapenem non-
susceptibility concordance (between ertapenem and imi-
penem, meropenem, doripenem) emerges once ertapenem
MIC values are 4 mg/mL. This finding indicates that we
likely could prescribe any of the other three carbapenem
agents to treat infections caused by ertapenem-NS (MICs
ranging from 0.5 to 2 mg/mL) Enterobacteriaceae without
KPC production. The clinical application of these valuable
in vitro susceptibility data, however, requires evaluation by
well-designed clinical trials.
In comparison to b-lactam agents, tigecycline and
colistin grossly showed low (<20%) in vitro nonsusceptible
rates against carbapenem-NS Enterobacteriaceae isolates
during the period 2010e2012 in Taiwan.6,7 Furthermore,
the activity of colistin against KPC-2-producing isolates
appears to be similar to that of tigecycline with regard to
in vitro susceptibility, despite the fact that the activity of
tigecycline was assessed with the criteria proposed by the
U.S. Food and Drug Administration (2 mg/mL; defined as
susceptible category).6 Nevertheless, the international
spread of genetic elements encoding KPC is still a worri-
some concern because of the escalating trend toward
nonsusceptibility to these two novel agents after clinical
use,10,11 and because infections due to KPC are associated
with a high case fatality rate.12
Currently, there is no specific infection control strategy
for carbapenem-NS Enterobacteriaceae. We think that
therapy comprising multiple antibiotics as well as contact
isolation are appropriate measures for dealing with in-
fections caused by pandrug-resistant KPC-producing
Enterobacteriaceae isolates in clinical settings. Periodic
targeted surveillance and development of new effective
antimicrobial drugs are urgently needed.Conflicts of interest
All authors report no conflicts of interest relevant to this
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